*Staphylococcus aureus and Streptococcus pyogenes.
S. aureus; S. pyogenes
Impetigo is a common and highly contagious bacterial skin infection.1 It is caused by either Staphylococcus aureus, Streptococcus pyogenes, or both2
Impetigo causes red, itchy sores. The sores can be anywhere on the body, but are most often on exposed areas of skin, like on the face around the nose and mouth, hands, arms, and legs. These sores break open and leak a clear fluid for a few days. They then form a yellowish crust1,3
Although impetigo occurs mostly in children between the ages of 2 and 5 years, people of any age can be affected3
Impetigo is highly contagious and can easily spread throughout a family or within groups that have close contact with each other1,3
Anyone with skin-to-skin contact, like parents and siblings, children in school, or people on sports teams, can spread impetigo with unwashed hands or with shared towels, sheets, clothing, toys, or other personal items1,3
To help keep this bacterial infection from spreading to others, people with impetigo are advised to stay home from work or school until the infected sores have healed (dried) or until after at least 24 hours of antibiotic treatment1,3
An antibiotic treatment prescribed by your doctor can not only stop impetigo from spreading to family and friends, it can also help impetigo go away faster2
If not treated, an impetigo infection could continue for 2 to 3 weeks, which could affect your child’s ability to go to school or daycare and your ability to go to work2
Cream or ointment antibiotics are usually the treatment chosen first by doctors and will usually need to be used for 5 to 7 days2,4,5
Uses: Xepi® is a topical prescription medicine approved for the treatment of impetigo, a skin infection caused by the bacteria Staphylococcus aureus or Streptococcus pyogenes, and is approved for adults and children two months of age and older.
When using this product:
Most common side effects were:
Pregnancy Warning: There is no available data on Xepi® use in pregnant women to inform a drug associated risk.
Lactation Warning: There is no available data regarding the presence of the active ingredient (ozenoxacin) in human milk, or the effects of ozenoxacin on the breastfed infant or on milk production.
Pediatric Warning: The safety and effectiveness of Xepi® in the treatment of impetigo have been established in patients 2 months to 17 years of age. The safety profile of Xepi® in patients 2 months and older was similar to that of adults.
The safety and effectiveness of Xepi® have not been established in patients younger than 2 months of age.
Geriatric Warning: Clinical studies of Xepi® did not include sufficient numbers of patients aged 65 and older to find out whether they respond differently from younger patients.
Inactive Ingredients: benzoic acid, octyldodecanol, peglicol 5 oleate, pegoxol 7 stearate, propylene glycol, purified water, stearyl alcohol
References: 1. Impetigo. Mayo Clinic. Accessed June 10, 2021.